News & Events

News &
Events

Tarsier Pharma Announces Participation at ARVO 2024 Annual Meeting

May 4-9, 2024

Tarsier Pharma Announces Participation at ARVO 2024 Annual Meeting

Tarsier Pharma, Ltd, will attend the ARVO (Association for Research in Vision and Ophthalmology) 2024 Annual Meeting (click here for event page), taking place in Seattle, WA, on May 4-9, 2024.

During ARVO, the American Uveitis Society (AUS) will convene for their Spring 2024 Meeting (click here for event page) on May 4th at 6:00 PM. Tarsier Pharma is scheduled to attend this event. Notably, Dr. Eric Crowell will present the Phase III data from the recent TRS4Vision trial during the free papers section, anticipated to begin around 7:15 PM.

In addition, OIS will convene for the OIS Retina Innovation Summit (click here for event page) on May 4th, where Dr. Daphne Haim-Langford, Tarsier Pharma’s Founder and CEO will present the recent news regarding TRS01 and TRS02 programs.

 

About Tarsier Pharma

Tarsier Pharma is a clinical stage biopharmaceutical company, focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat immune-mediated blinding diseases in the front and back of the eye.

 

Contact:

Investor Relations Tarsier Pharma

[email protected]

Scroll to Top